Polysynaid 8000: Static control in gas-phase HDPE

The plant operated a chromium-catalysed gas-phase fluidised-bed HDPE unit and had used an imported antistatic agent since start-up. Its objective was to qualify an alternative supply and review treatment cost while maintaining reactor stability, catalyst productivity and powder quality. Those requirements made a controlled plant evaluation essential to its decision.

Static matters because charged fines can adhere to reactor surfaces and contribute to sheets or lumps that disrupt operation. The plant therefore needed to look beyond static readings alone. Distributor-plate behavior, lump indications, discharge performance and powder properties all formed part of the evidence needed to assess whether the substitution program was working as intended.

Polysynaid 8000 is Cestoil's macromolecular antistat for polyethylene processing. The plant had a single antistat tank, so the trial used progressive blending through the existing tank rather than an immediate complete changeover. The proportion of Polysynaid 8000 was increased in stages while the operating team followed the reactor response.

This arrangement is important when reading the results. The incumbent remained in the antistat mixture during the documented trial. The report's favorable assessment of Polysynaid 8000 should therefore be considered with the recorded blend proportions and operating history. The observed period provides evidence for the monitored substitution program; it is not a completed trial of operation on Polysynaid 8000 alone.

The trial ran from December 2023 into January 2024 and included multiple HDPE grades and chromium-catalyst batches. During the evaluation, an upstream ethylene-plant trip required a change in feed supply and a reduction in production rate, followed by a return toward the earlier operating rate. Early feed after the upstream restart also introduced an impurity-related operating concern.

Cestoil's engineer remained at the site throughout the run. The team reviewed static changes against grade transitions, catalyst batches, feed conditions and production rate, adjusting antistat dosing in response. This event-based assessment was central to the trial: a static excursion needed to be understood in its process context before the team could judge the treatment response.

Static was monitored at three reactor probes. The broader monitoring set included catalyst productivity, distributor-plate temperature and pressure differences, reactor temperature indicators, lump detectors, bed density and cooling performance. The team also followed discharge behavior and the currents of the lump breakers and screens.

Powder records added another perspective. Particle size, particle appearance and flow behavior were assessed alongside reactor operation. This combination helped the technical team examine whether control of the static indicators was accompanied by acceptable process and product behavior. It also made the case relevant to a qualification decision involving an operating production unit, rather than only an isolated antistat-performance comparison.

The producer's commercial objective included lower treatment cost, but the trial report does not quantify a monetary saving. A comparable qualification should connect antistat consumption and cost with equivalent production rates, grades and catalyst conditions. Reactor stability and product indicators remain part of that assessment, since purchase price alone does not describe the value of the program.

The report recommends anticipating foreseeable static changes when planning treatment. For another plant, that means reviewing the history of grade transitions, catalyst changes and feed disturbances with the operating team. The appropriate response and dose remain site-specific and should be agreed through the reactor's own procedures and monitoring requirements.